AMAG Pharmaceuticals (AMAG)

[surf1944]

8:16AM AMAG Pharma announces Rienso receives Swiss Marketing Authorization for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (AMAG) 15.00 : Co announces that the Swiss Agency for Therapeutic Products has granted marketing authorization in Switzerland for ferumoxytol, an intravenous iron therapy to treat iron deficiency anemia in adult patients with chronic kidney disease. Ferumoxytol was approved for the same indication in the EU in June 2012, and in the US and Canada under the brand name Feraheme in June 2009 and December 2011, respectively. AMAG's partner, Takeda Pharmaceutical (TKPYY), is responsible for commercialization of ferumoxytol in Switzerland, the EU and Canada, among other territories. Takeda plans to launch ferumoxytol in Switzerland under the brand name Rienso. AMAG is entitled to receive tiered, double-digit royalties on product sales in the licensed territories. AMAG has sole commercial rights for Feraheme in the US.